---
confidence_score: 0.9
created: 2026-03-28T12:00:00+0000
description: Acylcarnitines are the transport form of activated fatty acids across
  the inner mitochondrial membrane. Formed by CPT-I from fatty acyl-CoA and carnitine,
  acylcarnitines are essential for long-chain fatty acid entry into the mitochondrial
  matrix for beta-oxidation and serve as critical diagnostic biomarkers for fatty
  acid oxidation disorders in newborn screening.
dg-home: false
dg-publish: true
evidence_level: 4
gardenUsername: itest781eb440
id: acylcarnitine
permalink: /garden/itest781eb440/metabolite/acylcarnitine/
provenance: curated
slug: acylcarnitine
source: Manual
tags:
- metabolite
- beta_oxidation
- energy_metabolism
- carnitine_shuttle
- fatty_acid_metabolism
- diagnostic_biomarker
templateEngineOverride: njk
title: Acylcarnitine
type: metabolite
updated: '2026-08-06T00:25:35.463960Z'
---

{% raw %}
<h1>Acylcarnitine</h1>
<h2>Overview</h2>
<p>Acylcarnitines are ester derivatives of carnitine formed by the transfer of an acyl group from fatty acyl-CoA to the hydroxyl group of carnitine. They serve as the exclusive transport vehicle for activated long-chain fatty acids across the inner mitochondrial membrane, which is impermeable to acyl-CoA esters. The carnitine shuttle system — comprising CPT-I (outer membrane), carnitine-acylcarnitine translocase (inner membrane antiporter), and CPT-II (matrix side) — is the rate-limiting gateway for beta-oxidation of long-chain fatty acids.</p>
<p>Because each acylcarnitine species corresponds to a specific fatty acyl chain length, acylcarnitine profiling by tandem mass spectrometry (MS/MS) has become the cornerstone of newborn screening for fatty acid oxidation disorders (FAODs). Characteristic accumulation patterns — such as elevated C8-acylcarnitine (octanoylcarnitine) in medium-chain acyl-CoA dehydrogenase (MCAD) deficiency — enable rapid, specific diagnosis from dried blood spots within days of birth.</p>
<p>Beyond their transport role, acylcarnitines have emerged as biomarkers of metabolic stress. Elevated plasma acylcarnitines, particularly medium- and long-chain species, correlate with insulin resistance, mitochondrial overload, and incomplete fatty acid oxidation in skeletal muscle. Accumulation of specific acylcarnitine species in tissues and plasma reflects the balance between fatty acid activation, transport capacity, and oxidative flux.</p>
<h2>The Carnitine Shuttle</h2>
<p>The carnitine shuttle is a three-component transport system that moves fatty acyl groups across the inner mitochondrial membrane:</p>
<h3>Step 1: Formation (CPT-I)</h3>
<p>Carnitine palmitoyltransferase I (CPT-I) on the outer mitochondrial membrane catalyzes the transfer of the acyl group from fatty acyl-CoA to carnitine, producing acylcarnitine and freeing CoA for cytosolic use. This is the committed and rate-limiting step of the shuttle.</p>
<ul>
<li><strong>Substrate:</strong> Fatty acyl-CoA + L-Carnitine</li>
<li><strong>Products:</strong> Acylcarnitine + CoA-SH</li>
<li><strong>Enzyme:</strong> CPT-I (three isoforms: liver CPT-IA, muscle CPT-IB, brain CPT-IC)</li>
<li><strong>Regulation:</strong> Inhibited by malonyl-CoA (the first committed intermediate of fatty acid synthesis), preventing simultaneous fat synthesis and fat oxidation</li>
</ul>
<h3>Step 2: Translocation (CACT)</h3>
<p>Carnitine-acylcarnitine translocase (CACT) is an antiporter in the inner mitochondrial membrane that exchanges one molecule of acylcarnitine (inward) for one molecule of free carnitine (outward), maintaining carnitine pool balance across the membrane.</p>
<ul>
<li><strong>Transport:</strong> Acylcarnitine (in) ↔ L-Carnitine (out)</li>
<li><strong>Protein:</strong> CACT (SLC25A20)</li>
<li><strong>Deficiency:</strong> CACT deficiency is a severe, often fatal FAOD presenting in the neonatal period</li>
</ul>
<h3>Step 3: Reconversion (CPT-II)</h3>
<p>CPT-II on the inner face of the inner mitochondrial membrane reverses the CPT-I reaction, transferring the acyl group back to CoA, regenerating fatty acyl-CoA for beta-oxidation and freeing carnitine for return transport.</p>
<ul>
<li><strong>Substrate:</strong> Acylcarnitine + CoA-SH</li>
<li><strong>Products:</strong> Fatty acyl-CoA + L-Carnitine</li>
<li><strong>Enzyme:</strong> CPT-II (single ubiquitously expressed isoform)</li>
<li><strong>Deficiency:</strong> CPT-II deficiency is the most common lipid myopathy, causing recurrent rhabdomyolysis triggered by exercise, fasting, or illness</li>
</ul>
<h3>Chain-Length Specificity</h3>
<table>
<thead>
<tr>
<th>Fatty Acid Chain Length</th>
<th>Primary Transport Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>C2 (acetate)</td>
<td>Free diffusion as acetyl-CoA or acetate</td>
</tr>
<tr>
<td>C4-C10 (short/medium)</td>
<td>Partial diffusion as acyl-CoA; some carnitine-independent transport</td>
</tr>
<tr>
<td>C12-C20 (long-chain)</td>
<td>Obligate carnitine shuttle via CPT-I/CACT/CPT-II</td>
</tr>
<tr>
<td>C22+ (very long-chain)</td>
<td>Carnitine shuttle + peroxisomal beta-oxidation first</td>
</tr>
</tbody>
</table>
<h2>Clinical Significance</h2>
<h3>Newborn Screening and FAOD Diagnosis</h3>
<p>Acylcarnitine profiling by tandem MS/MS is part of standard newborn screening panels worldwide. Key diagnostic patterns include:</p>
<table>
<thead>
<tr>
<th>Disorder</th>
<th>Elevated Species</th>
<th>Chain Length</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCAD deficiency</td>
<td>C8, C10, C10:1</td>
<td>Medium-chain</td>
</tr>
<tr>
<td>VLCAD deficiency</td>
<td>C14:1, C14, C12</td>
<td>Very long-chain</td>
</tr>
<tr>
<td>LCHAD/MTP deficiency</td>
<td>C16-OH, C18-OH, C18:1-OH</td>
<td>Long-chain hydroxy</td>
</tr>
<tr>
<td>CPT-I deficiency</td>
<td>Low total carnitine, elevated C0 ratio</td>
<td>Free carnitine dominance</td>
</tr>
<tr>
<td>CPT-II deficiency</td>
<td>C16, C18:1, C18</td>
<td>Long-chain</td>
</tr>
<tr>
<td>CACT deficiency</td>
<td>C16, C18:1, C18 + low C0</td>
<td>Long-chain + low free</td>
</tr>
</tbody>
</table>
<h3>Carnitine Supplementation</h3>
<p>L-Carnitine supplementation can restore acylcarnitine transport capacity in secondary carnitine deficiency states, including:</p>
<ul>
<li>Organic acidemias (where acyl-CoA esters deplete free carnitine)</li>
<li>Valproate therapy (which forms valproylcarnitine, depleting carnitine)</li>
<li>Renal tubular losses (Fanconi syndrome)</li>
<li>Premature infants (limited carnitine biosynthesis capacity)</li>
</ul>
<h3>Metabolic Disease Biomarkers</h3>
<p>Elevated plasma acylcarnitines serve as biomarkers for:</p>
<ul>
<li><strong>Insulin resistance:</strong> Incomplete fatty acid oxidation in skeletal muscle leads to acylcarnitine accumulation (especially C14:1, C16, C18:1)</li>
<li><strong>Heart failure:</strong> Accumulated acylcarnitines in failing myocardium reflect impaired fatty acid oxidation</li>
<li><strong>Sepsis and critical illness:</strong> Elevated acylcarnitine profiles indicate mitochondrial dysfunction</li>
</ul>
<h2>Relationships</h2>
<h3>Produced By</h3>
<p>PRODUCED_BY::<a href="/garden/itest781eb440/metabolite/fatty-acyl-coa/" class="internal-link">Fatty Acyl-CoA</a><br />
PRODUCED_BY::<a href="/garden/itest781eb440/protein/cpt-i/" class="internal-link">CPT-I</a></p>
<h3>Produces</h3>
<p>PRODUCES::<a href="/garden/itest781eb440/metabolite/fatty-acyl-coa/" class="internal-link">Fatty Acyl-CoA</a></p>
<h3>Participates In</h3>
<p>PARTICIPATES_IN_PATHWAY::<a href="/garden/itest781eb440/pathway/beta-oxidation/" class="internal-link">Beta-Oxidation</a></p>
<h3>Enzymes</h3>
<p>ACTIVATES::<a href="/garden/itest781eb440/protein/cpt-i/" class="internal-link">CPT-I</a><br />
ACTIVATES::<a href="/garden/itest781eb440/protein/cpt-ii/" class="internal-link">CPT-II</a></p>
<h3>Related Supplements</h3>
<p>RELATED::<a href="/garden/itest781eb440/supplement/l-carnitine/" class="internal-link">L-Carnitine</a></p>
<h3>Related Metabolites</h3>
<p>RELATED::<a href="/garden/itest781eb440/metabolite/coenzyme-a/" class="internal-link">Coenzyme A</a><br />
RELATED::<a href="/garden/itest781eb440/metabolite/acetyl-coa/" class="internal-link">Acetyl-CoA</a><br />
RELATED::<a href="/garden/itest781eb440/metabolite/nadh/" class="internal-link">NADH</a><br />
RELATED::<a href="/garden/itest781eb440/metabolite/atp/" class="internal-link">ATP</a><br />
RELATED::<a href="/garden/itest781eb440/metabolite/ketone-bodies/" class="internal-link">Ketone Bodies</a></p>
<h3>Organelles</h3>
<p>LOCATED_IN::<a href="/garden/itest781eb440/cellularcomponent/mitochondria/" class="internal-link">Mitochondria</a></p>
<h2>References</h2>
<ul>
<li>McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis. <em>Eur J Biochem.</em> 1997;244(1):1-14 (PMID: 9063439)</li>
<li>Wanders RJA, Visser G, Ferdinandusse S, Vaz FM, Houtkooper RH. Mitochondrial Fatty Acid Oxidation Disorders: Laboratory Diagnosis, Pathogenesis, and the Complicated Route to Treatment. <em>J Lipid Atheroscler.</em> 2020;9(3):313-333 (PMID: 33024728)</li>
<li>Merritt JL 2nd, Norris M, Kanungo S. Fatty acid oxidation disorders. <em>Ann Transl Med.</em> 2018;6(24):473 (PMID: 30740404)</li>
<li>Turgeon C, Magera MJ, Allard P, et al. Combined newborn screening for succinylacetone, amino acids, and acylcarnitines in dried blood spots. <em>Clin Chem.</em> 2008;54(4):657-664 (PMID: 18281422)</li>
<li>Koves TR, Ussher JR, Noland RC, et al. Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. <em>Cell Metab.</em> 2008;7(1):45-56 (PMID: 18177724)</li>
<li>Sim KG, Hammond J, Wilcken B. Strategies for the diagnosis of mitochondrial fatty acid beta-oxidation disorders. <em>Clin Chim Acta.</em> 2002;323(1-2):37-58 (PMID: 12135806)</li>
</ul>

{% endraw %}